Genome analysis ace opens in Boston Massachusetts
Genome analysis frontrunner SOPHiA GENETICS, which has an R & D base in Cambridge UK, has opened operations in America’s biotech capital of Boston.
The business is an acknowledged leader in data-driven medicine and is backed by Cambridge entrepreneur Dr Mike Lynch.
SOPHiA AI is regarded as the most widely used technology for genomic analysis, adopted by hundreds of university hospitals worldwide. It has already analysed over 250,000 genomic profiles – currently one every five minutes! Utilised in the context of hereditary disorders and cancer, SOPHiA enables clinicians to accurately detect and characterise genomic alterations.
Through the Swiss-headquartered company’s platform, experts can unite across borders and use their shared knowledge to efficiently deliver faster outcomes.
In the US, SOPHiA GENETICS is already supporting more than 100 university hospitals and is rapidly expanding across the region. It was ranked as one of the 50 smartest companies in the world by the MIT Tech Review.
Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, said: “We are experiencing a wide and fast adoption of our technology in North America and are very happy to open our US headquarters in Boston and strengthen our team to support customers’ needs.
“We currently have 20 people working in the US and we will be expanding to 50 within a year’s time.”
Lars Steinmetz, co-founder of SOPHiA GENETICS and professor at Stanford University added: “When we created SOPHiA GENETICS, we never expected to have such an impact worldwide.
“Thanks to the expertise and quality delivered by SOPHiA’s dedicated team of experts and its standardised technology, the company has earned the trust of the global genomics community, which is so important to truly accelerate the democratisation of data-driven medicine.”
Image: © 2017 SOPHiA GENETICS